Compandia Announces New Chairman

NOTTINGHAM, England, May 18, 2010 - Compandia is pleased to announce the appointment of its new non exec
chairman Dr Dave Tapolczay. Dave is CEO of Medical Research Council
Technology, the commercialisation company for the MRC. Compandia CEO, Andy
Sutton announced," We are thrilled that Dave has joined Compandia and will
bring significant experience from his years at GSK, Millenium, Pharmorphix
and AZ. Dave will add a strategic view from both the large International
Corporate and Start Up perspectives and bring a wealth of knowledge regarding
current trends affecting the Pharma and Biotech Sectors which will assist
Compandia in positioning its services for optimal delivery".

Compandia is a biomarker discovery and bioinformatics spin out from
Nottingham Trent University. Compandia uses advanced bioinformatics tools to
derive biomarker panels from complex biological data being generated in the
Pharmaceutical, Biotech and Biomedical sectors. Compandia's advantage is the
ability to find small biomarker panels from data that would otherwise be
impossible to decipher this enables disease states to be accurately diagnosed
from a small number of analytes.

Compandia in addition offers proteomic services coupled to its "Biomarker
Distiller" for the discovery of proteomic biomarker panels. Compandia has
successfully delivered panels of 3-6 proteins: for the stratification of
patients into responders and non responder prior to prostate cancer therapy;
for staging of melanoma patients based on a serum signature and
identification of mild cognitive impairment [MCI] patients as a clearly
defined cohort tending towards Alzheimer's disease. "Biomarker Distiller" has
also been applied to gene array, micro RNA array and Next Gen sequencing
datasets comfortably delivering biomarker panels of 3-8 genes defining
melanoma, breast prostate and lung cancer patient cohorts suitable for
therapy.

Compandia also announced the launch of a new bioinformatics capability,
its "Pathways Distiller" bioinformatics tool that creates maps of interacting
gene pathways which define patient populations such as drug responders from
non responders. This unique tool allows researchers to identify key nodes
where interactions take place that may represent new drug targets or offer
insight into mechanisms of therapy failure. Compandia CEO, Andy Sutton
explained, "Pathways Distiller gives us completely new insight into
biological states defined by detailed pathway maps which will prove
beneficial to companies planning combination therapies."

If you require further information please contact
Dr Andy Sutton CEO on +44(0)7764-580468 or e-mail
andy.suttton@compandia.co.uk, website www.compandia.co.uk

If you require further information please contact Dr Andy Sutton CEO on +44(0)7764-580468 or e-mail andy.suttton at compandia.co.uk